Current:Home > NewsUnanimous Supreme Court preserves access to widely used abortion medication-InfoLens
Unanimous Supreme Court preserves access to widely used abortion medication
View Date:2024-12-23 15:13:54
Live updates: Follow AP’s coverage of the Supreme Court’s decision to preserve access to mifepristone.
WASHINGTON (AP) — The Supreme Court on Thursday unanimously preserved access to a medication that was used in nearly two-thirds of all abortions in the U.S. last year, in the court’s first abortion decision since conservative justices overturned Roe v. Wade two years ago.
The justices ruled that abortion opponents lacked the legal right to sue over the federal Food and Drug Administration’s approval of the medication, mifepristone, and the FDA’s subsequent actions to ease access to it.
The case had threatened to restrict access to mifepristone across the country, including in states where abortion remains legal.
Justice Brett Kavanaugh wrote for the court that “federal courts are the wrong forum for addressing the plaintiffs’ concerns about FDA’s actions.” Kavanaugh was part of the majority to overturn Roe.
The high court is separately considering another abortion case, about whether a federal law on emergency treatment at hospitals overrides state abortion bans in rare emergency cases in which a pregnant patient’s health is at serious risk.
More than 6 million people have used mifepristone since 2000. Mifepristone blocks the hormone progesterone and primes the uterus to respond to the contraction-causing effect of a second drug, misoprostol. The two-drug regimen has been used to end a pregnancy through 10 weeks gestation.
Health care providers have said that if mifepristone is no longer available or is too hard to obtain, they would switch to using only misoprostol, which is somewhat less effective in ending pregnancies.
President Joe Biden’s administration and drug manufacturers had warned that siding with abortion opponents in this case could undermine the FDA’s drug approval process beyond the abortion context by inviting judges to second-guess the agency’s scientific judgments. The Democratic administration and New York-based Danco Laboratories, which makes mifepristone, argued that the drug is among the safest the FDA has ever approved.
The decision “safeguards access to a drug that has decades of safe and effective use,” Danco spokeswoman Abigail Long said in a statement.
The abortion opponents argued in court papers that the FDA’s decisions in 2016 and 2021 to relax restrictions on getting the drug were unreasonable and “jeopardize women’s health across the nation.”
Kavanaugh acknowledged what he described as the opponents’ “sincere legal, moral, ideological, and policy objections to elective abortion and to FDA’s relaxed regulation of mifepristone.”
But he said they went to the wrong forum and should instead direct their energies to persuading lawmakers and regulators to make changes.
Those comments pointed to the stakes of the 2024 election and the possibility that an FDA commissioner appointed by Republican Donald Trump, if he wins the White House, could consider tightening access to mifepristone.
The mifepristone case began five months after the Supreme Court overturned Roe. Abortion opponents initially won a sweeping ruling nearly a year ago from U.S. District Judge Matthew Kacsmaryk, a Trump nominee in Texas, which would have revoked the drug’s approval entirely. The 5th U.S. Circuit Court of Appeals left intact the FDA’s initial approval of mifepristone. But it would reverse changes regulators made in 2016 and 2021 that eased some conditions for administering the drug.
The Supreme Court put the appeals court’s modified ruling on hold, then agreed to hear the case, though Justices Samuel Alito, the author of the decision overturning Roe, and Clarence Thomas would have allowed some restrictions to take effect while the case proceeded.
___
Follow the AP’s coverage of the U.S. Supreme Court at https://apnews.com/hub/us-supreme-court.
veryGood! (9968)
Related
- KFC sues Church's Chicken over 'original recipe' fried chicken branding
- California judge who allegedly texted court staff that he shot his wife pleads not guilty
- Toyota, Chrysler among nearly 270,000 vehicles recalled last week: Check car recalls here.
- OK, we can relax. The iPhone ‘hang up’ button might not be moving much after all
- NFL power rankings Week 11: Steelers, Eagles enjoying stealthy rises
- Carlos De Oliveira, Mar-a-Lago property manager, pleads not guilty in classified documents case
- ‘Wounded Indian’ sculpture given in 1800s to group founded by Paul Revere is returning to Boston
- Israel may uproot ancient Christian mosaic near Armageddon. Where it could go next sparks outcry
- Dwayne 'The Rock' Johnson weighs in on report that he would 'pee in a bottle' on set
- US-focused Opera News, to cease publication in November after 87 years
Ranking
- Dramatic video shows Phoenix police rescue, pull man from car submerged in pool: Watch
- Magoo, Timbaland's former musical partner, dies at 50
- We Ranked All of Mary-Kate and Ashley Olsen's Movies and You Will Definitely Do a Double-Take
- The problem with treating Bama Rush TikTokers like famous reality stars
- Mike Tyson is expected to honor late daughter during Jake Paul fight. Here's how.
- Breaking up big business is hard to do
- Auto parts maker Shinhwa plans $114M expansion at Alabama facility, creating jobs
- Former NFL star Michael Oher, inspiration for The Blind Side, claims Tuohy family never adopted him
Recommendation
-
Taylor Swift touches down in Kansas City as Chiefs take on Denver Broncos
-
'Another day in the (Smokies)': Bear dashes across Tennessee high school football field
-
Museum to honor Navajo Code Talkers is about $40 million shy of reality
-
ESPN, anchor Sage Steele part ways after settling lawsuit
-
Will Trump’s hush money conviction stand? A judge will rule on the president-elect’s immunity claim
-
Capture the best candid shots with bargains on Nikon cameras at B&H
-
Indiana revokes licenses of funeral home and director after decomposing bodies and cremains found
-
Toronto Maple Leafs Prospect Rodion Amirov Dead at 21 After Brain Tumor Diagnosis